This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Schafer-N, Universitaetsklinikum Hamburg-Eppendorf. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 5,383 
1 out of 2 
1 out of 7 Years Active: 2008
Title: Geneviève Rougon: Innovator in Neurodegenerative Disease Treatment
Introduction
Geneviève Rougon is a prominent inventor based in Marseilles, France. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patents. His work focuses on the modulation of neural cell adhesion molecule (NCAM) functions, which is crucial for understanding and treating various neurological conditions.
Latest Patents
Geneviève Rougon holds a patent titled "Use of poly-α2,8-sialic acid mimetic peptides to modulate NCAM functions." This invention relates to a peptide consisting of 5 to 30 amino acid residues, specifically designed to interact with NCAM. The peptide, which includes a B epitope of poly-α2,8 sialic acid, is recognized by an anti-poly-α2,8 sialic acid antibody. It is intended for the preparation of a medicament aimed at preventing and treating neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer. This patent highlights Rougon's commitment to advancing medical science and improving patient outcomes.
Career Highlights
Throughout his career, Geneviève Rougon has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and Université de la Méditerranée Aix-Marseille. His research has been pivotal in exploring the therapeutic potential of peptides in neurological applications. Rougon's dedication to innovation has positioned him as a key figure in the scientific community.
Collaborations
Geneviève Rougon has collaborated with notable colleagues, including Pascal Torregrossa and Melitta Schachner. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in the field of neurobiology.
Conclusion
Geneviève Rougon's contributions to the understanding and treatment of neurodegenerative diseases through his patented innovations demonstrate his significant impact on medical research. His work continues to inspire advancements in therapeutic strategies for complex neurological conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile